Supply chain efficiency and sourcing for scaling your gene therapy operation

Cell & Gene Therapy Insights 2022; 8(3), 523

DOI: 10.18609/cgti.2021.077

Published: 3 May 2022
Céline Martin, Don Young

Scale-up for clinical and commercial gene therapy manufacturing impacts both process and operations. In the wake of SARS-CoV-2, supply chains have been significantly challenged and raw materials are in short supply. As the potential of gene therapies is being realized, long-term sustainable manufacture needs to be considered.